Aptevo Therapeutics Files 8-K for Material Agreement

TL;DR

APVO filed an 8-K for a material definitive agreement - details to follow.

AI Summary

Aptevo Therapeutics Inc. announced on June 28, 2024, that it entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits as part of this 8-K filing. Specific details of the agreement and financial information were not provided in the excerpt.

Why It Matters

This filing indicates a significant development for Aptevo Therapeutics, potentially involving new partnerships, acquisitions, or financing that could impact its future operations and stock value.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce significant opportunities or risks depending on their terms, which are not fully detailed in this initial filing.

Key Players & Entities

• Aptevo Therapeutics Inc. (company) — Registrant
• June 28, 2024 (date) — Date of earliest event reported
• 20240628 (date) — Conformed period of report
• 20240701 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value APVO The Nasdaq Stock Mar
• $0.515 — ommon Warrants") at a purchase price of $0.515 per share and associated Common Warrant
• $0.5149 — priced at a combined offering price of $0.5149 per Pre-Funded Warrant and accompanying
• $0.0001 — d accompanying Common Warrants less the $0.0001 per share exercise price of each such P
• $27.28 — Common Stock and have exercise price of $27.28 per share, (ii) November 9, 2023 to pur
• $10.252 — Common Stock and have exercise price of $10.252 per share, and (iii) April 15, 2024 to
• $1.35 — Common Stock and have exercise price of $1.35 per share (collectively, the "Existing
• $2.3 million — received net proceeds of approximately $2.3 million from the offering, after deducting the

Filing Documents

• apvo-20240628.htm (8-K) — 58KB
• apvo-ex4_1.htm (EX-4.1) — 162KB
• apvo-ex4_2.htm (EX-4.2) — 155KB
• apvo-ex10_1.htm (EX-10.1) — 159KB
• apvo-ex10_2.htm (EX-10.2) — 316KB
• apvo-ex10_3.htm (EX-10.3) — 165KB
• apvo-ex10_4.htm (EX-10.4) — 155KB
• apvo-ex10_5.htm (EX-10.5) — 159KB
• apvo-ex10_6.htm (EX-10.6) — 174KB
• apvo-ex10_7.htm (EX-10.7) — 159KB
• apvo-ex10_8.htm (EX-10.8) — 173KB
• apvo-ex99_1.htm (EX-99.1) — 15KB
• apvo-ex99_2.htm (EX-99.2) — 16KB
• img237228349_0.jpg (GRAPHIC) — 4KB
• img238151870_0.jpg (GRAPHIC) — 4KB
• 0000950170-24-079653.txt ( ) — 2298KB
• apvo-20240628.xsd (EX-101.SCH) — 25KB
• apvo-20240628_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. The information regarding the Purchase Agreement (as defined below) set forth in Item 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 1.01.

01 Other Events

Item 8.01 Other Events. On June 28, 2024, Aptevo Therapeutics Inc. (the "Company") announced that it has entered into a securities purchase agreement (the "Purchase Agreement") with certain healthcare-focused institutional investors to purchase (i) 5,339,806 shares of its common stock, par value $0.001 per share ("Common Stock"), or pre-funded warrants to purchase shares of Common Stock ("Pre-Funded Warrants") in lieu thereof and (ii) warrants to purchase up to an aggregate of 10,679,612 shares of Common Stock (the "Common Warrants") at a purchase price of $0.515 per share and associated Common Warrants in a registered direct offering priced at-the-market under Nasdaq Stock Market rules. The Purchase Agreement contains customary representations, warranties and agreements of the Company and the purchasers and customary indemnification rights and obligations of the parties. Each share of Common Stock or Pre-Funded Warrant in lieu thereof was offered together with two Common Warrants, each to purchase one share of Common Stock. The Common Warrants have an exercise price of $0.515 per share, are exercisable upon stockholder approval, and will expire five years following the date of stockholder approval. The exercise price of the Common Warrants is subject to adjustment for stock splits and similar capital transactions and is subject to repricing in the event of a share split, share dividend, share combination or other such event as described in the Common Warrants. The Pre-Funded Warrants and accompanying Common Warrants were priced at a combined offering price of $0.5149 per Pre-Funded Warrant and accompanying Common Warrants, which is equal to the offering price per share of Common Stock and accompanying Common Warrants less the $0.0001 per share exercise price of each such Pre-Funded Warrant. The Pre-Funded Warrants are immediately exercisable and terminate when exercised in full. In connection with the offering, the Company entered into a Placement Agency Agre

01 Other Events

Item 8.01 Other Events The Company issued press releases announcing the offering and the closing of the offering on June 28, 2024 and July 1, 2024, respectively. Copies of these press releases are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Description 4.1 Common Warrant, dated July 1, 2024. 4.2 Pre-Funded Warrant, dated July 1, 2024. 10.1 Placement Agency Agreement dated June 28, 2024, between the Company and Roth Capital Partners. 10.2 Securities Purchase Agreement, dated June 28, 2024, between the Company and the purchasers party thereto. 10.3 Form of Amended Common Warrant, dated as of July 1, 2024, between the Company and certain warrant holders. 10.4 Form of Amended Series A Common Warrant, dated as of July 1, 2024, between the Company and certain warrant holders. 10.5 Form of Amended Series A-1 Common Warrant, dated as of July 1, 2024, between the Company and certain warrant holders. 10.6 Form of Amended Series A-2 Common Warrant, dated as of July 1, 2024, between the Company and certain warrant holders. 10.7 Form of Amended Series B-1 Common Warrant, dated as of July 1, 2024, between the Company and certain warrant holders. 10.8 Form of Amended Series B-2 Common Warrant, dated as of July 1, 2024, between the Company and certain warrant holders. 99.1 Press Release of Aptevo Therapeutics Inc., dated June 28, 2024. 99.2 Press Release of Aptevo Therapeutics Inc., dated July 1, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. APTEVO THERAPEUTICS INC. Date: July 1, 2024 By: /s/ Marvin L. White Marvin L. White President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR